A decades-old drug, initially developed to treat a rare hormonal disorder, is showing remarkable promise as a potential weapon against the most deadly form of lung cancer. Researchers at Ohio University have discovered that blocking the growth hormone receptor (GHR) can significantly enhance the effectiveness of chemotherapy in Non-Small Cell Lung Cancer (NSCLC), a disease … Read more
A significant, yet predictably complex, victory has emerged in the fight against small cell lung cancer (SCLC). New data from the ADRIATIC trial demonstrates that durvalumab, an immunotherapy drug, substantially extends both overall and progression-free survival for patients with limited-stage SCLC. However, this clinical triumph is immediately shadowed by a familiar challenge in oncology: astronomical … Read more
Small cell lung cancer (SCLC), a relentlessly aggressive disease, has long defied effective long-term treatment. While initial responses to chemotherapy are often promising, the near-inevitable relapse and rapid progression have left a significant unmet need for deeper understanding of the cancer’s underlying mechanisms. Now, a breakthrough study from the University of Cologne is shedding light … Read more